Anaplastic large cell lymphoma (ALCL) is a distinct subset of T鄄 cell non鄄 Hodgkin爷s lymphoma. As a consequence of its low incidence, general pathogenic consideration of ALCL is lacking. In this review, we summarize the pathogenesis, epidemiology, clinical manifestations, and treatment of ALCL, so as to better understand key stages of the development of this disease and provide valuable information for future treatment.
Anaplastic large cell lymphoma (ALCL), an aggressive nonHodgkin爷s lymphoma (NHL), is classified as a type of peripheral Tcell lymphoma by the World Health Organization (WHO) and accounts for 2% to 7% of diagnosed NHL cases. ALCL has several distinct characteristics: tumor cells are anaplastic and strongly CD30 (Ki1)positive, tending to grow in clusters and invade lymph nodes; about half of the patients with ALCL have abnormal oncogenic anaplastic lymphoma kinase (ALK) fusion proteins. ALCL tumors are divided into ALKpositive (ALK + ALCL) and ALKnegative ALCL (ALK ALCL), according to the expression of ALK. Because of a low incidence of ALCL and poor understanding of the pathogenesis, clinical awareness of ALCL is limited and the disease is commonly misdiagnosed. This review focuses on the research progresses of its pathogenesis and briefly covers ALCL epidemiology, clinical features and treatment.
Epidemiology
According to the U.S. epidemiological survey, from 1992 to 2001, ALCL accounted for about 0.8% of all lymphomas and 13.9% of T/NK cell lymphomas; the annual incidence was 0.25 per 100 000 people, which was higher among Caucasians and African Americans (0.34 and 0.38 per 100 000 people, respectively) over Asian Americans (0.17 per 100 000 people). The incidence ratios of male to female were 1.9 (Caucasians), 2.0 (African Americans) and 1.3 (Asian Americans). According to the WHO classification, ALCL accounts for 3% of adult lymphomas and 10% to 30% of child lymphomas . In Asia, ALCL has a lower overall incidence.
Pathogenesis

ALK + ALCL
Recent advances in clinical and basic researches showed that ALK + ALCL may originated from transformed T lymphocytes and the pathogenesis was mainly associated with ALKrelated chromosomal translocation [1] . However, the causes for chromosomal translocation (such as DNA damage, especially doublestranded DNA breaks, and DNA repair, in particular those involving nonhomologous DNA recombination) and the exact origin of tumor cells are still poorly understood.
In the 1980爷s, ALK (CD246), as a new receptor tyrosine kinase (RTK) belongs to the insulin receptor superfamily, was identified through studies of ALCL chromosomal translocation [2, 3] . In human beings, the gene (GenBank accession No.U62540, U66559) is localized at 2p23 and has 26 exons; the 6222 bp cDNA www.cjcsysu.com . Full鄄 length ALK is a single鄄 pass transmembrane protein containing 1621 amino acid residues which can be divided into three parts: extracellular (N鄄 terminal), transmembrane, and intracellular (C鄄 terminal) segments. The extracellular segment mainly contains four functional domains: a signal peptide, a ligand鄄 binding region, a LDL鄄 A and MAM region, and a glycine鄄 rich region (numbers in parenthesis represent the spanning amino acid residues of each region). The intracellular segment contains two major domains: a tyrosine kinase domain and a juxtamembrane region.
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Pathogenesis of anaplastic large cell lymphoma encodes a 1620aa typeI transmembrane protein with a predicted molecular weight of 177 kDa; after posttranslational modification (mainly Nglycosylation), mature ALK has an apparent weight of 200 kDa. In mice, the gene (GenBank accession No.D83002) is localized on chromosome 17 and encodes a 1621aa protein Alk, sharing 85% homology with human ALK. ALK consists of a 1030aa Nterminal extracellular segment, a 28aa transmembrane segment, and a 562aa Cterminal intracellular segment (Figure 1) . The extracellular segment contains 1) a signal peptide (the hydrophobic 26aa Nterminal) guiding transmembrane traffic; 2) a ligandbinding domain (residues 391401) binding endogenous ligand pleiotrophin (PTN) or midkine (MK); 3) a low density lipoproteinA (LDLA) and MAM domain (residues 480635, a homology domain of meprins, A5 protein and receptor protein tyrosine phosphates mu), of which MAM domain may be involved in intercellular interactions; 4) a glycinerich domain close to a transmembrane segment; and 5) 16 Nglycosylation sites (NXS/T) and 26 serine residues (residues 425487 and 9871021 forming two serine clusters). The intracellular segment includes 1) a membraneperipheral region (residues 10591122) containing a binding site (residues 10931096) of insulin receptor substrate1 (IRS1), facilitating a tyrosine phosphorylationdependent interaction; 2) a tyrosine kinase catalytic region (residues 11231376) containing the kinase activity loop that consists of threetyrosine motif (Y1278, Y1282 and Y1283), and the tyrosine phosphorylationdependent Src binding site; and 3) the Cterminal region (residues 13771620) containing tyrosine phosphorylation dependent SH2 domaincontaining transforming protein (Shc) and phospholipase Cgamma (PLC酌 ) binding sites (residues 15041507 and residues 16031606, respectively) [4] .The threetyrosine motif in the tyrosine kinase catalytic region is the major selfphosphorylation site of the insulin receptor superfamily. Tyrosine selfphosphorylation changes the conformation of the activity loop, facilitating the access of ATP into the ATPbinding pocket and activating ALK.
In normal tissues, spatiotemporal expression of ALK is restricted, peaking during the prenatal period and decreasing rapidly after birth. In human beings, mRNA is predominantly transcribed in the brain and intestinal nervous tissues, scattering in the testis, placenta, and fetal liver; in mic e, mRNA is predominantly transcribed in the brain and peripheral nervous system. Alk may function as a dependence receptor (inhibiting apoptosis at the presence of ligand and inducing apoptosis after ligand removal) regulating cell survival by interacting with PTN or MK, thus participating in the nervous system development. However, knockout mice show no obvious developmental defects in morphology or function, suggesting that ALK is not a key regulator in mammalian development [5] .
ALK is expressed in certain nonhematologic tumors (such as rhabdomyosarcoma, glioblastoma and breast cancer) and a few hematologic tumors (such as few diffuse large Bcell lymphoma) [4] . However, the high expression of ALK in ALK + ALCL is due to the chromosomal translocation of gene. Most breaks occur in the intron between exons 16 and 17. As exons 17 through 26 encode the intracellular segment of ALK, the Cterminal segment of the fusion/chimeric protein lacks the extracellular and transmembrane segments. Since all partner protein genes at the 5' end of the fusion gene are widely expressed, the ALK fusion protein is constitutively expressed under the control of the 5' end partner protein gene promoter in ALK + ALCL. In addition, some partner proteins at the Nterminus of the ALK fusion protein contain a coiledcoil domain (such as TFG and TPM), or a hydrophobic region (such as NPM), or are an inherent homodimer or multimer (such as ATIC and CLTC). Therefore, ALK fusion proteins can form homologous or heterologous oligomeric complexes. The MSNALK fusion protein is an exception, however. Although moesin has no oligomeric motif, it can attach ALK onto the cell membrane, facilitating ALK interactions with its partners. Although ALK fusion proteins lack the extracellular ligandbinding segment, oligomerization can lead to ALK activation and selfphosphorylation, thereby activating a series of downstream signaling pathways [6] . The prognosis of many patients with chromosomal translocation is similar, indicating that ALK activation may be a key link in the pathogenesis of ALK + ALCL. Thus translocation, the most frequent translocation of , has became the 野molecular machine冶 model from which almost all chimeric ALK signaling pathways originate [1, 6] . Studies showed that, through several intracellular signaling pathways, activated ALK regulates cell proliferation, apoptosis, morphology, migration, and invasion, regulates tumor cell phenotype and mediates tumor cell transformation. As a shortrange positive feedback mechanism ensuring continuous activation of ALK, some downstream molecules (such as Src and Jak3) phosphorylate ALK.
Regulation of the cell cycle and apoptosis by ALK Activated ALK regulates cell proliferation and apoptosis mainly through the Rasextracellular signalregulated kinase (Erk), Janus kinase 3 (JAK3)signal transducers and activators of transcription 3 (STAT3), and phosphatidylinositol 3kinase (PI3K)Akt/protein kinase B (PKB) signaling pathways ( Figure 2) .
As mentioned, the tyrosine phosphorylation sites in the tyrosine kinase (TK) domain of activated ALK recruit Src; the tyrosine phosphorylation sites in the membraneperipheral regions and Cterminal segment recruit IRS1 and Shc, respectively, activating the RasErk pathway [7, 8] . However, recent studies suggest that the recruitment of IRS1 and Shc is not the key step in activating the RasErk pathway. Activated ALK can recruit and activate SH2 domaincontaining tyrosine phosphatase 2 (Shp2), activate the RasErk pathway by triggering growth factor receptorbound protein 2son of sevenless (Grb2SOS) or Src [9, 10] . In addition, the ALK Cterminus contains a PLC酌 binding site, facilitating PLC酌 interaction and activation, stimulating the RasErk pathway via PLC酌 DAG/IP3Ca 2+ PKC [11] . Activated RasErk can upregulate cyclin A and cyclin D1, activate activated protein1 (AP1) [12] , and phosphorylate and activate Jun Nterminal kinase (JNK), which in turn phosphorylates cJun and activates AP1; activated AP1 can induce the expression of cyclin A and cyclin D3, and downregulate p21 expression [13] . Mammalian target of rapamycin (mTOR) may also be activated by the RasErk pathway, triggering its downstream effectors such as p70 ribosomal protein S6 kinase (p70S6K), S6 ribosomal protein (S6RP), and eukaryotic initiation factor 4Ebinding protein 1 (eIF4EBP1) [14] . In summary, activated ALK facilitates RasErk pathway activation, the upregulation of cyclins (cyclin A, cyclin D1, and cyclin D3), the downregulation of cyclin kinase inhibitor (p21), and the activation of protein translationrelated regulatory factors (p70S6K, S6RP, eIF4EBP1), accelerating cell proliferation and inhibiting apoptosis.
Activated ALK can activate STAT3 directly by phosphorylation or indirectly by activating Jak3, which in turn phosphorylates and activates STAT3. Activated STAT can form a homodimer and functions as a transcription factor, inducing the transcription of some antiapoptotic and proproliferation factors, such as Bcl2, BclX L , myeloid cell leukemia sequence 1 (MCL1), and cyclin D3, while activating antiapoptotic transcription factors, such as survivin and CEBP茁 [1518] . In addition, Jak2STAT5B may induce cell proliferation and inhibit apoptosis by cooperating with Jak3STAT3 [19] . Activated ALK can activate PI3K by binding to the p85 subunit of PI3K; activated PI3K phosphorylates and activates Akt1/Akt2, and then insulates Bad and suppresses p27 by phosphorylation [2022] . In addition, forkhead box transcription factor O3A (FOXO3A) can be phosphorylated by activated Akt, which can block its entry into the nucleus, thereby inhibiting the expression of p27 and Bim while upregulating cyclin D2 [23] . These signals synergistically orchestrate the inhibition of apoptosis and abnormal cell cycle progression. Moreover, Akt activation can also activate the mTOR pathway , but its effect is weaker than RasErk pathway [14, 24] .
Regulation of cell immunophenotype by ALK The activation of ALK stimulates the RasErk pathway, then phosphorylates JunB and upregulates AP1. In addition, activation of the Jak3/STAT3 pathway leads to the dimerization of STAT3 after being phosphoryled, resulting in the upregulation of CD30 transcription [18, 25] .
Regulation of cell transformation, migration, and invasion by ALK Activated ALK activate several downstream effectors (Src, Shp2 and p130 Crkassociated substrate) which can cause the . After spontaneous oligomerizaton or induction by cytoplasmic factors, the activation of chimeric ALK triggers transforming events, such as proliferation and apoptosis inhibition, cellular immunophenotyping (CD30 up鄄 regulation), and abnormal morphological changes (anaplasia), migration and invasion. Following ALK activation, the recruitment of IRS鄄 1, Src, and Shc and the subsequent stimulation of Shp2鄄 Grb2/SOS, Shp2鄄 Src, and PLC酌 鄄 DAG/IP3鄄 PKC could synergistically activate the RAS鄄 Erk pathway, up鄄 regulating the expression of cyclin A and cyclin D, and down鄄 regulating the expression of p21, which could also be a target of the JUK鄄 Jun鄄 AP1 pathway triggered by ALK activation. In addition, the PI3K鄄 PIP3鄄 Akt and Jak3鄄 STAT3 pathways also could be triggered by the activation of ALK. As a result, cyclin D expression would be abnormally regulated, the expression of Bcl2/Bcl鄄 X L , Bim, MCL1, survivin would be up鄄 regulated, whereas the expression of p27 and Bad would be down鄄 regulated. Consequently, these abnormally regulated cell cycle鄄 and apoptosis鄄 related molecules could stimulate cell proliferation and inhibit apoptosis. Moreover, Ras鄄 Erk and PI3K鄄 PIP3鄄 Akt activation could target mTOR to stimulate certain translation鄄 associated factors (such as p70S6K, S6RP, and eIF4EBP1) and enhance cell proliferation. Stimulating the Ras鄄 Erk and Jak3/STAT3 pathways could induce JunB phosphorylation and AP1 up鄄 regulation, and STAT3 dimerization in the nucleus, respectively. As a result, the transcriptional activity of CD30 gene would increase. The simulation of Src, Shp2, p130Cas, and Vav鄄 Rac1 could be induced by ALK activation. As a consequence, cytoskeletal arrangement and dynamics would be abnormally regulated, inducing changes in morphology (anaplasia) and transformation (migration and invasion). Green arrows represent activation or up鄄 regulation; red semi鄄 bars represent inhibition or down鄄 regulation.
Proliferation, apoptosis inhibition
Cell membrane rearrangement of cytoskeletal proteins, such as filamentous actin, whose abnormal assembly can lead to cell deformation [8, 10, 26] . In addition, activated ALK can phosphorylate guanine nucleotide exchange factors (GEFs) from the Vav family, which in turn can activate GTPase (such as Rac1) from the Rho family and induce cell migration and invasion [27] .
Recent studies have shown that Shp1 and STAT5A promoters are hypermethylated in ALK + ALCL, inhibiting their transcriptional activity. Shp1 can inhibit the activity of ALK and STAT3, and STAT5A also represses ALK activity, therefore, the suppression of Shp1 and STAT5A may promote the tumorigenesis of ALCL [28, 29] , supporting the hypothesis that epigenetic suppression plays a role in the pathogenesis of ALK + ALCL. In addition to being a cell surface antigen in ALK + ALCL, CD30 is involved in the pathogenesis. Although the underlying mechanism is not clear, CD30 is closely related to ALCL staging. At early onset, CD30 expression and activation can induce cell apoptosis, then CD30 participates in a series of regulatory steps involving the cell cycle and apoptosis by activating the NF资 B pathway (both canonical and noncanonical) [1, 18, 30] . Furthermore, other studies suggest that heat shock protein 90 (HSP90), Sucassociated neurotrophic factorinduced phosphorylated target/fibroblast receptor substrates (SNT/FRS), and nuclear interacting partner of anaplastic lymphoma kinase (NIPA) are also involved in the cell transformation of ALK + ALCL, but the underlying mechanisms need further clarification [1] . Current studies on ALK + ALCL pathogenesis are limited to the functions of ALK. Little is known about its partner proteins, with understanding restricted to their effects on ALK subcellular localization. Note that many studies on signaling pathways are based on experiments or with cell lines and may not reflect the scenario . For example, many studies have shown that transgenic mice and cells do not necessarily develop into ALCL. Therefore, the exact mechanism of pathogenesis of ALK + ALCL requires further research and clinicians need to be very cautious before using particular signal molecules for targeted therapy. ALCL is classified as a separate disease, possessing a similar morphology to ALK + ALCL [31] . In absence of exact etiology, specific genetic mutation, and characteristic genetic markers, the pathogenesis of ALK ALCL is poorly understood. However, when comparing indicators of clinical treatment and prognosis with the abnormal expression of molecules associated with ALK ALCL, investigators found that apoptotic dysregulation may be involved in ALK ALCL pathogenesis. The infiltration of activated cytotoxic T lymphocytes (CTLs) has been observed in ALK ALCL [32] . Granzyme B, which is released from CTLs, can induce cell apoptosis directly by activating Caspase3 or indirectly by activating Bid, leading to the release of cytochrome C from mitochondria [33, 34] . ALK ALCL cells have been shown to express protease inhibitor 9 (PI9), which functions as an intracellular serine proteinase inhibitor that inhibit tumor cell apoptosis by inhibiting the activity of CTLreleased granzyme B [35, 36] . Meanwhile, due to a feedback regulatory mechanism, increased tumor infiltration by activated CTLs enhances cell apoptosis in the surrounding normal tissues. Furthermore, ALK ALCL cells have a higher expression of Bcl2 and other antiapoptotic proteins, which can inhibit the mitochondriamediated apoptosis pathway, and lower expression of caspase3 precursor, which also can inhibit apoptosis [37] . However, the above pathways involving in the inhibition of apoptosis are not unique to ALK ALCL; on the contrary, many tumors use similar mechanisms to suppress apoptosis. Therefore, some investigators suggest that ALK ALCL may represent the endstage pathology of various Tcell lymphomas [38] .
Clinical Manifestations
Clinical symptoms of ALK + ALCL are as follows: (1) early onset, most patients are less than 30 years old [39, 40] ; (2) male predominance, with a male to female ratio of 1.22:1; (3) superficial and abdominal lymphadenectasis often appears, large tumors are very common, accounting for 30 % 54 % , accompanied by inguinal lymphadenectasis in about 40% of the pediatric cases; mediastinal invasion is rarer in ALCL than in Hodgkin disease (HD); 25% of the patients have splenomegaly; (4) most patients are already in the late stage (stage IIIIV) at diagnosis and are often accompanied by B symptoms (75% ), especially a high temperature [40, 41] ; (5) extranodal invasion is common (60%) and about 40% of the patients have 2 or more extranodal lymphomas; (6) bone marrow metastases are detected in 11% of the patients by HE staining and in 30% of the patients by immunohistochemical staining (expression of CD30 and p80 in bone marrow cells). ALK ALCL usually occurs in an older population (mostly aged 45 to 60 years old). Hodgkinlike ALCL in a younger population and 85% of the patients are ALK and are usually in stage IIA. About 60% of the patients have an enlarged mediastinum, but have no skin or bone metastasis. These clinical manifestations are significantly different from that of ALK + ALCL [42, 43] . Secondary ALCL, derived from other lymphomas such as mycosis fungoides, peripheral Tcell lymphoma, HD, and lymphomatoid papulosis, often occurs in older people. ALK typing predicts poor prognosis. In 2008, Savage . [44] showed that ALK ALCL has a similar incidence of extranodal invasion as ALK + ALCL. ALK + ALCL frequently metastasizes to the bone marrow, bone, subcutaneous tissue and spleen, whereas ALK ALCL frequently metastasizes to the skin, liver and gastrointestinal tract.
The ALCL involving peripheral blood and bone marrow metastasis was termed as the 野leukemic phase冶 ALCL, and has a low incidence and poor prognosis, regardless of ALK expression [45] .
Treatments
Because of a low incidence of ALCL, its treatment and prognosis have seldom been reported, and there were no standardized treatment protocols of ALCL. Most studies on ALCL treatment are retrospective, focusing on conventional chemotherapy or highdose chemotherapy combined hematopoietic stem cell transplantation. Currently, most ALCL patients are treated with multidrug combination chemotherapy supplemented with radiotherapy. The patients with ALK + ALCL are sensitive to chemotherapy and have a higher longterm survival rate. The 5year survival rate of ALK + ALCL patients is 71% 93% , significantly higher than that of ALKALCL patients (15%40%). The 2010 NCCN Clinical Practical Guideline recommends that the selection of ALCL treatments should be based on staging and prognosis indices. Two options are clinical trials or combined chemotherapy with involvedfield radiotherapy. Highdose chemotherapy with autologous stem cell transplantation (ASCT) can be used as a salvage therapy. A large series of retrospective studies on peripheral Tcell lymphoma have shown that most patients with ALCL received multidrug chemotherapy or anthracyclinebased chemotherapy, 5 ALK ALCL patients and 6 ALK + ALCL patients received ASCT as the initial treatment; the overall response rate of initial treatment was 88% in ALK + ALCL patients and 76% in ALK ALCL patients, with the 5year overall survival (OS) of ALK + and ALK ALCL patients higher than failurefree survival (FFS) (in ALK + patients, 70% vs. 60% ; in ALK patients, 49% vs. 36% ) [46] , indicating that ASCT salvage therapy may be effective for certain cases.
Hence, the best strategy for the treatment of ALCL is still in question [4749] . Most investigators recommend a preceding evaluation on ALK, IPI, and other prognostic factors before choosing a treatment strategy. For patients incurring drug resistance or relapse from firstline therapy, secondline therapy or new drugs can be applied to improve the prognosis. New ALCL targeted drugs include CD30 monoclonal antibody, CD25 monoclonal antibody, and denileukin2. Summary ALCL has a low incidence and its occurrence is a complicated multistep process. Currently, no ideal treatment for ALCL caused by the abnormal activation of ALK and its downstream signaling pathways is available. In this review, we summarized key mechanisms underlying the pathogenesis, clinical manifestations, and treatment, provide insight for future therapy.
